That's true, and if it's been going on, it can now proceed with redoubled speed, assuming they didn't also reduce the a/s at the same ratio.....
I see that there's an offering planned... and, at today's price, the amount of shares needed with be close to 4x the amount as of the offering date. due to the precipitous price decline. The dilution will be devastating.
Ya can’t fight dilution….
Split adjusted, I see this was over $150 early in 2022....Yikes. Is there anything worth looking at with the company? Why has it dropped so much? Was it shorted?
I just heard about it, and was wondering. I know nothing of the company. Sorry, folks.
Looks like a panelrequest or r s to satisfy NASDAQ. Only 17 million outstanding and 1 for 20 should give the outstanding at sub 1 million. The 80s gap will necessitate a $16 ballpark to fill. MMS trying to create panic selling to cover but fuck them. If they initiate a r s soon they'll be in a big dog pile situation. Hold your shares as the squeeze thereafter will be epic!!
Only a few trades a year look this good,super low risk/insane high reward,40% insider,bulls loading last 6 days macd flipped to buy,big news is coming with all this buying and bid humping and short covering,102k shares short,trial starting,manufacturers contract and supply agreement inbound,long target is $4.90,I can’t find a down side with book pps .42 and cash pps .51,not optionable so no less mm games,EF Hutton buy rating with 2.25 target,6 institutions new buys,sabby up 1139% FOLLOW THE $ FOR ME
$BBLG: Trying to bounce higher at 0.24
On watch here amigos
Revenues chit the bed ! <> $0.00
BBLG .34 New price target out $7.50
$BBLG FDA accepted pilot study from Australia, multibillion-dollar spinal fusion market, targeted bone regeneration, exclusive global license to its proprietary tech & heavy insider ownership - biotech stock to watch
Bone Biologics Shares Spike Following Recent Zack's Small Cap Research Report Showing $8 Valuation Target
CONGRAT$ BBLG Nov 01 2021 5.48 0.48 9.6% 5.2013 5.6796 5.09 550,033
Bone Biologics Shares Up 60% Premarket; An Amended 13D Filing on Monday from Hankey Capital, LLC Showed a 69% Stake.
Bone Biologics Corporation is a medical device company. The Company is focused on bone regeneration in spinal fusion using the recombinant human protein, known as NELL-1/DBX. The NELL-1/DBX combination product is an osteostimulative recombinant protein that provides target specific control over bone regeneration. Its platform technology has application in delivering improved outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It develops a platform technology through laboratory and small and large animal research to generate the applications across fields of use. The platform technology is its human protein, known as NELL-1, a skeletal specific growth factor which is a bone void filler. NELL-1 provides regulation over skeletal tissue formation and stem cell differentiation during bone regeneration.